Analysed ENTRADA THERAPEUTICS INC (TRDA:NASDAQ) News Sources
Entrada Therapeutics Announces Positive Topline Results from Cohort 1 of Participants with Duchenne Muscular Dystrophy Treated with ENTR-601-44 in Phase 1/2 ELEVATE-44-201 Study
07-05-2026
yahoo.com
Independent Safety Data Monitoring Committee Recommends Initiation of Cohort 2 at the Increased Dose of 10 mg/kg in Entrada Therapeutics’ ELEVATE-45-201 Study
02-06-2026
yahoo.com
Entrada Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
02-09-2026
yahoo.com
Entrada Therapeutics Announces Recipients of Fourth Annual DREAMS Grant Program
10-09-2026
yahoo.com
Entrada Therapeutics Announces Positive Results from the First Cohort of Participants with Duchenne Muscular Dystrophy (DMD) in the Phase 1/2 ELEVATE-45-201 Study of ENTR-601-45
14-10-2026
yahoo.com
Independent Safety Data Monitoring Committee Recommends Initiation of Cohort 3 at the Top Dose of 18 mg/kg in Entrada Therapeutics’ ELEVATE-44-201 Study
14-10-2026
yahoo.com
What is the current price of ENTRADA THERAPEUTICS INC (TRDA:NASDAQ)?
The current price of ENTRADA THERAPEUTICS INC (TRDA:NASDAQ) is $4.75.
ENTRADA THERAPEUTICS INC (TRDA:NASDAQ) absolute price change since previous trading day?
The absolute price change of ENTRADA THERAPEUTICS INC (TRDA:NASDAQ) since the previous trading day is $0.34.
ENTRADA THERAPEUTICS INC (TRDA:NASDAQ) percentage price change since previous trading day?
The percentage price change of ENTRADA THERAPEUTICS INC (TRDA:NASDAQ) since the previous trading day is 7.7098%.
What is the most recent average sentiment score for ENTRADA THERAPEUTICS INC (TRDA:NASDAQ)?
The most recent average sentiment score for ENTRADA THERAPEUTICS INC (TRDA:NASDAQ) is 55 out of 100.
What is the most recent average sentiment for ENTRADA THERAPEUTICS INC (TRDA:NASDAQ)?
The most recent sentiment for ENTRADA THERAPEUTICS INC (TRDA:NASDAQ) is .
SEC-8K** Filing Available For ENTRADA THERAPEUTICS INC (TRDA:NASDAQ)
** material developments that could impact a company's financial condition or stock price.
Author: MattELab
MattELab is the founder and lead developer of SentientMerchant. With a Computer Science and Quantitative Finance background from a T10 university, he brings over 6 years of expertise in NLP, programmatic SEO, and full-stack development to build highly scalable AI and FinTech solutions.